Oracle will integrate Nuance Communications' cloud-based medical speech recognition technology
Focused on improving productivity of clinical programs, reducing costs, and boosting study participant retention, health sciences organizations seek ways to accelerate and streamline clinical trial data collection and management. To support these objectives, Oracle will integrate Nuance Communications' (NASDAQ: NUAN) cloud-based medical speech recognition technology with Oracle Health Sciences e-clinical software.
News Facts
“Nuance’s medical speech and language understanding solutions allow people to stay productive by leveraging mobile devices, and cloud connectivity to communicate anywhere, anytime across devices and platforms,” said Peter Durlach, senior vice president marketing, Nuance Communications. “Embedding Nuance cloud-based medical speech solutions into Oracle’s clinical apps provides a more natural and efficient approach for clinical researchers and staff to deliver accurate information within their workflow.”
· “Clinical trial sponsors and contract research organizations around the world count on Oracle Health Sciences’ leading e-clinical solutions to help them automate and streamline their entire clinical development process,” said Nick Giannasi, vice president, Oracle Health Sciences. “We are committed to continued innovation, and working with Nuance will bring powerful voice-driven capabilities to our e-clinical solutions, making it easier and faster for investigators and study participants to capture and provide accurate clinical trial data.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.